The longitudinal course of cognitive impairment in schizophrenia: An examination of data from premorbid through posttreatment phases of illness

Journal of Clinical Psychiatry

Volumn 75, Issue SUPPL. 2, 2014, Pages 8-13

  Keefe, Richard S E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ACADEMIC ACHIEVEMENT; ARTICLE; COGNITIVE DEFECT; DETERIORATION; DISEASE COURSE; HUMAN; MENTAL PERFORMANCE; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; CHILD DEVELOPMENT; COGNITION; DATA ANALYSIS; DRUG RESPONSE; FUNCTIONAL STATUS; PEER GROUP; STUDY DESIGN;

COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; PRODROMAL SYMPTOMS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84904561204     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13065su1.02     Document Type: Article

References (55)

1. Pollack M, Woerner M, Klein DF. A comparison of childhood characteristics of schizophrenics, personality disorders, and their siblings. In: Roff M, Ricks DF, eds. Life History Research in Psychopathology. Minneapolis, MN: University of Minnesota Press; 1970:208-225.
2. Parnas J, Schulsinger F, Schulsinger H, et al. Behavioral precursors of schizophrenia spectrum: a prospective study. Arch Gen Psychiatry. 1982;39(6):658-664. doi:10.101/archpsyc.1982.0429060205 PubMed (Pubitemid 12078959)
3. Aylward E, Walker E, Bettes B. Intelligence in schizophrenia: meta-analysis of the research. Schizophr Bull. 1984;10(3):430-459. doi:10.1093/schbul/10.3.430 PubMed
4. Mirsky AF, Silberman EK, Latz A, et al. Adult outcomes of high-risk children: differential effects of town and kibbutz rearing. Schizophr Bull. 1985;11(1):150-154. doi:10.1093/schbul/1.1.150 PubMed
5. Parnas J, Schulsinger H. Continuity of formal thought disorder from childhood to adulthood in a high-risk sample. Acta Psychiatr Scand. 1986;74(3):246-251. doi:10.1/j.160-047.1986.tb06240.x PubMed (Pubitemid 17175351)
6. Done DJ, Crow TJ, Johnstone EC, et al. Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ. 1994;309(6956):699-703. doi:10.136/bmj.309.6956.69 PubMed (Pubitemid 24285221)
7. Jones P, Rodgers B, Murray R, et al. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344(8934):1398-1402. doi:10.1016/S0140-6736(94)90569-X PubMed (Pubitemid 24365314)
8. Payne R. Cognitive abnormalities. In: Eysenck HJ, ed. Handbook of Abnormal Psychology. New York, NY: Basic Books; 1961:193-261.
9. Schwartzman AE, Douglas VI, Muir WR. Intellectual loss in schizophrenia. II. Can J Psychol. 1962;16(2):161-168. doi:10.1037/h083240 PubMed
10. Smith A. Mental deterioration in chronic schizophrenia. J Nerv Ment Dis. 1964;139(5):479-487. doi:10.1097/05053-196410-08 PubMed
11. Silverberg-Shalev R, Gordon HW, Bentin S, et al. Selective language deterioration in chronic schizophrenia. J Neurol Neurosurg Psychiatry. 1981;44(6):547-551. doi:10.136/jnp.4.6.547 PubMed (Pubitemid 11046560)
12. Meier MH, Shalev I, Moffitt TE, et al. Microvascular abnormality in schizophrenia as shown by retinal imaging. Am J Psychiatry. 2013;170(12):1451- 1459. doi:10.176/api.ajp.2013.13020234 PubMed
13. Reichenberg A, Caspi A, Harrington H, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry. 2010;167(2):160-169. doi:10.176/api.ajp.209.09040574 PubMed
14. Haywood HC, Moelis I. Effect of symptom change on intellectual function in schizophrenia. J Abnorm Soc Psychol. 1963;67(1):76-78. doi:10.1037/h046251 PubMed
15. Klonoff H, Fibiger CH, Hutton GH. Neuropsychological patterns in chronic schizophrenia. J Nerv Ment Dis. 1970;150(4):291-300. doi:10.1097/05053-197040-04 PubMed
16. Heaton RK, Crowley TJ. Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. In: Felskov SB, Boll TJ, eds. Handbook of Clinical Neuropsychology. Vol 1. New York, NY: John Wiley & Sons; 1981:481-525.
17. Nopoulos P, Flashman L, Flaum M, et al. Stability of cognitive functioning early in the course of schizophrenia. Schizophr Res. 1994;14(1):29-37. doi:10.1016/0920-964(94)906-X PubMed (Pubitemid 24372781)
18. DeLisi LE, Tew W, Xie S, et al. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol Psychiatry. 1995;38(6):349-360. doi:10.1016/06-323(94)0376-E PubMed
19. Sweeney JA, Haas GL, Keilp JG, et al. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year followup study. Psychiatry Res. 1991;38(1):63-76. doi:10.1016/0165-1781(91)9053- R PubMed
20. Censits DM, Ragland JD, Gur RC, et al. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res. 1997;24(3):289-298. doi:10.1016/S0920-964(96)091-6 PubMed (Pubitemid 27163240)
21. Hoff AL, Riordan H, O'Donnell DW, et al. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry. 1992;149(7):898-903. PubMed
22. Calev A, Venables PH, Monk AF. Evidence for distinct verbal memory pathologies in severely and mildly disturbed schizophrenics. Schizophr Bull. 1983;9(2):247-264. doi:10.1093/schbul/9.2.247 PubMed (Pubitemid 13071293)
23. Levin S, Yurgelun-Todd D, Craft S. Contributions of clinical neuropsychology to the study of schizophrenia. J Abnorm Psychol. 1989;98(4):341-356. doi:10.1037/021-843X.98.4.341 PubMed (Pubitemid 20066207)
24. Green M, Walker E. Neuropsychological performance and positive and negative symptoms in schizophrenia. J Abnorm Psychol. 1985;94(4):460-469. doi:10.1037/021-843X.94.4.460 PubMed (Pubitemid 16159634)
25. Green M, Walker E. Attentional performance in positive- and negativesymptom schizophrenia. J Nerv Ment Dis. 1986;174(4):208-213. doi:10.1097/05053-1986040-03 PubMed (Pubitemid 16042318)
26. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48(7):618-624. doi:10.101/archpsyc.191.018103103607 PubMed
27. Goldberg TE, Hyde TM, Kleinman JE, et al. Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophr Bull. 1993;19(4):797-804. doi:10.1093/schbul/19.4.797 PubMed (Pubitemid 23339436)
28. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull. 1984;10(2):160-203. doi:10.1093/schbul/10.2.160 PubMed
29. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31(9):2033-2046. doi:10.1038/sj.np.1301072 PubMed
30. Hammer MA, Katsanis J, Iacono WG. The relationship between negative symptoms and neuropsychological performance. Biol Psychiatry. 1995;37(11):828-830. doi:10.1016/06-323(95)040-N PubMed
31. Strauss ME. Relations of symptoms to cognitive deficits in schizophrenia. Schizophr Bull. 1993;19(2):215-231. doi:10.1093/schbul/19.2.215 PubMed (Pubitemid 23183146)
32. Cuesta MJ, Peralta V. Cognitive disorders in the positive, negative, and disorganization syndromes of schizophrenia. Psychiatry Res. 1995;58(3):227-235. doi:10.1016/0165-1781(95)02712-6 PubMed
33. Liddle PF. Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psychol Med. 1987;17(1):49-57. doi:10.1017/ S032917012976 PubMed (Pubitemid 17055153)
34. Braff DL. Sensory input deficits and negative symptoms in schizophrenic patients. Am J Psychiatry. 1989;146(8):1006-1011. PubMed (Pubitemid 19197977)
35. Strauss ME, Buchanan RW, Hale J. Relations between attentional deficits and clinical symptoms in schizophrenic outpatients. Psychiatry Res. 1993;47(3):205-213. doi:10.1016/0165-1781(93)9079-V PubMed (Pubitemid 23190380)
36. Nuechterlein KH, Edell WS, Norris M, et al. Attentional vulnerability indicators, thought disorder, and negative symptoms. Schizophr Bull. 1986;12(3):408-426. doi:10.1093/schbul/12.3.408 PubMed
37. Cornblatt BA, Lenzenweger MF, Dworkin RH, et al. Positive and negative schizophrenic symptoms, attention, and information processing. Schizophr Bull. 1985;11(3):397-408. doi:10.1093/schbul/1.3.397 PubMed (Pubitemid 15036183)
38. Green M, Walker E. Susceptibility to backward masking in schizophrenic patients with positive or negative symptoms. Am J Psychiatry. 1984;141(10):1273-1275. PubMed (Pubitemid 14011512)
39. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203-213. doi:10.176/api.ajp.207.0701042 PubMed (Pubitemid 351704520)
40. Keefe RSE, Fox KH, Harvey PD, et al. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011;125(2-3):161-168. doi:10.1016/j.schres.2010.09.015 PubMed
41. August SM, Kiwanuka JN, McMahon RP, et al. The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates. Schizophr Res. 2012;134(1):76-82. doi:10.1016/j.schres.201.10.015 PubMed
42. Umbricht D, Keefe RS, Murray S, et al. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia [published online ahead of print January 27, 2014]. Neuropsychopharmacology. doi:10.1038/np.2014.17 PubMed
43. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157(4):549-559. doi:10.176/api.ajp.157.4.549 PubMed (Pubitemid 30191193)
44. Keefe RSE, Eesley CE. Neurocognition of schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan and Sadock Comprehensive Textbook of Psychiatry; Philadelphia, PA: Lippincot Williams & Wilkins; 2009:1531-1541.
45. Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;57(6):688-691. doi:10.1016/j.biopsych.205. 01.03 PubMed (Pubitemid 40409709)
46. Seidman LJ, Giuliano AJ, Meyer EC, et al North American Prodrome Longitudinal Study (NAPLS) Group. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry. 2010;67(6):578-588. doi:10.101/ archgenpsychiatry.2010.6 PubMed
47. Davidson M, Reichenberg A, Rabinowitz J, et al. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999;156(9):1328-1335. PubMed (Pubitemid 29416527)
48. Bilder RM, Reiter G, Bates J, et al. Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol. 2006;28(2):270-282. doi:10.1080/13803905036054 PubMed (Pubitemid 43254519)
49. Fuller R, Nopoulos P, Arndt S, et al. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry. 2002;159(7):1183-1189. doi:10.176/api.ajp.159.7.183 PubMed (Pubitemid 34743259)
50. Keefe RSE, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and metaanalysis. Schizophr Bull. 1999;25(2):201-222. doi:10.1093/oxfordjournals. schbul.a0374 PubMed (Pubitemid 29272501)
51. Woodward ND, Purdon SE, Meltzer HY, et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007;89(1-3):211-224. doi:10.1016/j.schres.206.08.021 PubMed (Pubitemid 44881296)
52. Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166(6):675-682. doi:10.176/api.ajp.208.08060806 PubMed
53. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158(2):176-184. doi:10.176/api.ajp.158.2.176 PubMed (Pubitemid 32116511)
54. Keefe RS, Bilder RM, Davis SM, et al Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64(6):633-647. doi:10.101/archpsyc.64.6.63 PubMed (Pubitemid 46878665)
55. Keefe RS, Malhotra AK, Meltzer HY, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology. 2008;33(6):1217-1228. doi:10.1038/sj.np.130149 PubMed (Pubitemid 351521707)